Johnson GV - Search Results

1

Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.

Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR, Leavitt BR. Van Raamsdonk JM, et al. Among authors: johnson gv. J Neurochem. 2005 Oct;95(1):210-20. doi: 10.1111/j.1471-4159.2005.03357.x. J Neurochem. 2005. PMID: 16181425 Free article.

2

Tissue transglutaminase is increased in Huntington's disease brain.

Lesort M, Chun W, Johnson GV, Ferrante RJ. Lesort M, et al. Among authors: johnson gv. J Neurochem. 1999 Nov;73(5):2018-27. J Neurochem. 1999. PMID: 10537061 Free article.

3

Does tissue transglutaminase play a role in Huntington's disease?

Lesort M, Chun W, Tucholski J, Johnson GV. Lesort M, et al. Among authors: johnson gv. Neurochem Int. 2002 Jan;40(1):37-52. doi: 10.1016/s0197-0186(01)00059-6. Neurochem Int. 2002. PMID: 11738471 Review.

4

Axin negatively affects tau phosphorylation by glycogen synthase kinase 3beta.

Stoothoff WH, Bailey CD, Mi K, Lin SC, Johnson GV. Stoothoff WH, et al. Among authors: johnson gv. J Neurochem. 2002 Nov;83(4):904-13. doi: 10.1046/j.1471-4159.2002.01197.x. J Neurochem. 2002. PMID: 12421363 Free article.

5

Tau, where are we now?

Johnson GV, Bailey CD. Johnson GV, et al. J Alzheimers Dis. 2002 Oct;4(5):375-98. doi: 10.3233/jad-2002-4505. J Alzheimers Dis. 2002. PMID: 12446970 Review.

6

The p38 MAP kinase signaling pathway in Alzheimer's disease.

Johnson GV, Bailey CD. Johnson GV, et al. Exp Neurol. 2003 Oct;183(2):263-8. doi: 10.1016/s0014-4886(03)00268-1. Exp Neurol. 2003. PMID: 14552867 Review. No abstract available.

7

Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.

Bailey CD, Graham RM, Nanda N, Davies PJ, Johnson GV. Bailey CD, et al. Among authors: johnson gv. Mol Cell Neurosci. 2004 Mar;25(3):493-503. doi: 10.1016/j.mcn.2003.11.016. Mol Cell Neurosci. 2004. PMID: 15033177

8

Developmental regulation of tissue transglutaminase in the mouse forebrain.

Bailey CD, Johnson GV. Bailey CD, et al. Among authors: johnson gv. J Neurochem. 2004 Dec;91(6):1369-79. doi: 10.1111/j.1471-4159.2004.02825.x. J Neurochem. 2004. PMID: 15584913 Free article.

9

Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.

Bailey CD, Johnson GV. Bailey CD, et al. Among authors: johnson gv. J Neurochem. 2005 Jan;92(1):83-92. doi: 10.1111/j.1471-4159.2004.02839.x. J Neurochem. 2005. PMID: 15606898 Free article.

10

Transglutaminases in neurodegenerative disorders.

Bailey CD, Tucholski J, Johnson GV. Bailey CD, et al. Among authors: johnson gv. Prog Exp Tumor Res. 2005;38:139-57. doi: 10.1159/000084238. Prog Exp Tumor Res. 2005. PMID: 15746534 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

269 results

Search Page

Filters